Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that the United States Patent and Trademark Office has granted U.S. Patent Number 9,707,333 (the ‘333 Patent), entitled “EXTRACORPOREAL REMOVAL OF MICROVESICULAR PARTICLES.”
The ‘333 Patent covers methods of capturing exosomes that include an MHC-I or MHC-II antigen, whereby a patient suspected of receiving a benefit from exosome capture and removal is selected, and the whole blood, plasma, or serum from the patient is contacted with a substrate that includes antibodies specific for an MHC-I or MHC-II antigen. The ‘333 Patent also covers methods of capturing and removing MHC-I or MHC-II antigen associated exosomes from whole blood, plasma, or serum of a patient, and returning the whole blood, plasma, or serum to the patient with substantially fewer MHC-I or MHC-II antigen associated exosomes.
MHC-I and MHC-II antigen associated exosomes contribute to the progression of numerous disease conditions, including cancer, autoimmune disorders and neurodegenerative diseases.
The ‘333 Patent is a continuation of U.S. Patent Number 9,364,601, which covers methods of lectin-based capture of exosomes from a patient, and U.S. Patent Number 8,288,172, which protects the use of the Aethlon Hemopurifier® in a method to remove immunosuppressive exosomes from blood. Together, these patents solidify Aethlon’s position as a leader in pioneering diagnostic and therapeutic strategies in the field of exosome biology.
Aethlon Chairman and CEO Jim Joyce stated, “In addition to expanding our intellectual property portfolio, the issuance of the ‘333 patent further reinforces our competitive position within the emerging industry for therapeutic strategies to inhibit the proliferation of disease-promoting exosomes.”
Source – PR Newswire
Extracorporeal removal of microvesicular particles
US 9364601 B2
The invention described herein teaches methods of removing microvesicular particles, which include but are not limited to exosomes, from the systemic circulation of a subject in need thereof with the goal of reversing antigen-specific and antigen-nonspecific immune suppression. Said microvesicular particles could be generated by host cells that have been reprogrammed by neoplastic tissue, or the neoplastic tissue itself. Compositions of matter, medical devices, and novel utilities of existing medical devices are disclosed.
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A method of capturing an exosome from a patient on a surface that comprises a lectin, said method comprising:
identifying a patient for exosome capture and contacting an exosome from said patient with a surface that comprises a lectin thereby capturing said exosome. (read more…)